

Brent Willis on Voyageur Pharmaceuticals' competitive suite of barium radiographic contrast media products

written by InvestorIntel | June 22, 2021

In a recent InvestorIntel interview, Chris Thompson speaks with Brent Willis, President and CEO of [Voyageur Pharmaceuticals Ltd.](#) (TSXV: VM) about Health Canada's approval for their 5th licensed product in their full suite of barium radiographic contrast media products for global sales and distribution.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Brent touches on their recent successful financing and an update on Voyageur moving forward with its business plan of becoming the only fully-integrated company in the radiographic contrast medical field. Furthermore, Brent explains how with their own source of feedstock for its products provides Voyageur with a competitive cost advantage, makes Voyageur the only pharmaceutical radiographic contrast company to utilize its own mineral resource. Brent sums it up when he states: "We are coming to market with the lowest ingredient cost."

To watch the full interview, [click here](#)

About Voyageur Pharmaceuticals Ltd.

Voyageur Pharmaceuticals Ltd. is a Canadian public company listed on the TSX Venture Exchange under the trading symbol VM. Voyageur is focused on the development of barite and iodine, Active Pharmaceutical Ingredient (API) minerals. The near-term

focus is developing barium and iodine radio-contrast pharmaceutical products. Voyageur's goal is to initially generate near term positive cash flow from operations using third party GMP pharmaceutical manufacturers in Canada and internationally. Ultimately, Voyageur has plans to build all the required infrastructure to become 100% self-sufficient with all manufacturing. Voyageur owns a 100% interest in three barium sulfate (barite) projects including two properties suitable in grade for the industrial barite marketplace, with interests in a potentially high-grade iodine, lithium & bromine brine project located in Utah, USA.

Voyageur is moving forward with its business plan of becoming the only fully-integrated company in the radiographic contrast medical field, by controlling all primary input costs under the motto of: "From the Earth to the Bottle"

To learn more about Voyageur Pharmaceuticals Ltd., [click here](#)

Disclaimer: Voyageur Pharmaceuticals Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional

risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on www.Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email info@investorintel.com.